Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones.

Estradiol (E2) replacement therapy effectively prevents or delays postmenopausal bone loss, but the mode of E2 action on bone is still unknown. Recently, the presence of E2 receptors was described for bone-derived cells. In this study we examined the estrogen responsiveness of osteoblastic cells using the experimentally immortalized calvarial cell lines RCT-1 and RCT-3 as well as primary cultures of calvarial and trabecular bone cells. E2 treatment reduced PTH-stimulated adenylate cyclase activity by 20-30% in RCT cells; the maximum effect was observed after treatment with 1 nM E2 for 4 h or longer. In trabecular cells E2 decreased PTH-stimulated adenylate cyclase activity by 60-80%. After a lag period of at least 48 h, E2 treatment (0.01-10 nM) increased cell number and [3H]thymidine incorporation in both RCT-3 cells and primary cultures of trabecular cells to 20-60% above control values. Half-maximal effects were observed at about 1 nM E2. Antibodies against insulin-like growth factor-I (IGF-I) inhibited the E2-induced proliferation in a dose-dependent manner without affecting basal growth. Furthermore, E2 treatment increased the steady state levels of IGF-I mRNA 2- to 2.5-fold in calvarial and RCT-3 cells compared to control levels. In addition, E2 (10 nM) increased the level of collagen mRNA more than 2-fold and opposed the suppression of collagen mRNA produced by PTH treatment. The E2 effects were specific to 17 beta-E2, since they were not observed with the biologically less active stereoisomer 17 alpha-E2 and were blocked by the E2 antagonist tamoxifen (1 microM). Thus, for osteoblastic cells in culture, E2 can directly stimulate proliferation as well as collagen and IGF-I mRNA while decreasing PTH responsiveness; these effects could explain the anabolic and anticatabolic effects of E2 on bone.

[1]  C. Londos,et al.  A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.

[2]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. , 1978, The Journal of biological chemistry.

[3]  D. Kaufman,et al.  Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. , 1988, Molecular endocrinology.

[4]  W. Welshons,et al.  Estrogenic activity of phenol red , 1988, Molecular and Cellular Endocrinology.

[5]  B. Komm,et al.  Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. , 1988, Science.

[6]  D. Kaufman,et al.  Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. , 1986, Cancer research.

[7]  C. Roberts,et al.  Molecular cloning of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues. , 1987, Molecular endocrinology.

[8]  J. Gorski,et al.  Control of estrogen binding protein concentration under basal conditions and after estrogen administration. , 1971, Biochemistry.

[9]  E. Froesch,et al.  Release of insulin-like growth factor carrier proteins by osteoblasts: stimulation by estradiol and growth hormone. , 1989, Biochemical and biophysical research communications.

[10]  D. Feldman,et al.  Distinction between alpha-fetoprotein and intracellular estrogen receptors: evidence against the presence of estradiol receptors in rat bone. , 1978, Endocrinology.

[11]  G. Wesolowski,et al.  Growth stimulation of rat calvaria osteoblastic cells by acidic fibroblast growth factor. , 1987, Endocrinology.

[12]  D. Rowe,et al.  Parathyroid hormone alters collagen synthesis and procollagen mRNA levels in fetal rat calvaria. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Rodan,et al.  Type β transforming growth factor (TGFβ) regulation of alkaline phosphatase expression and other phenotype‐related mRNAs in osteoblastic rat osteosarcoma cells , 1987 .

[14]  S. Farmer,et al.  Differential expression of two neural cell-specific beta-tubulin mRNAs during rat brain development , 1984, Molecular and cellular biology.

[15]  T. Flynn,et al.  17 beta-estradiol acts directly on the clonal osteoblastic cell line UMR106. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Kenneth G. Mann,et al.  Evidence of estrogen receptors in normal human osteoblast-like cells , 1988 .

[17]  G. Bell,et al.  Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. , 1987, Endocrinology.

[18]  A. Tashjian,et al.  Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. , 1989, Endocrinology.

[19]  S. Kukreja,et al.  Effects of estradiol and progesterone on parathyroid hormone secretion from human parathyroid tissue. , 1988, The Journal of clinical endocrinology and metabolism.

[20]  S. Rodan,et al.  Rat calvarial cell lines immortalized with SV-40 large T antigen: constitutive and retinoic acid-inducible expression of osteoblastic features. , 1989, Endocrinology.

[21]  J. Cidlowski,et al.  Sex-related differences in the regulation of cytoplasmic estrogen receptor levels in responsive tissues of the rat. , 1976, Endocrinology.

[22]  G. Bell,et al.  Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. , 1987, Endocrinology.

[23]  R. Lindsay,et al.  LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENT , 1976, The Lancet.

[24]  L. Mathews,et al.  Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. , 1988, Endocrinology.

[25]  R. Baxter,et al.  Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. , 1988, Biochemical and biophysical research communications.

[26]  E. Canalis,et al.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.

[27]  D. Rowe,et al.  Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. , 1984, Biochemistry.

[28]  E. Froesch,et al.  Enhanced osteoblast proliferation and collagen gene expression by estradiol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Froesch,et al.  Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. , 1988, Biochemical and biophysical research communications.

[30]  L. Bonewald,et al.  Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Froesch,et al.  Actions of insulin-like growth factors. , 1985, Annual review of physiology.

[32]  R L Hintz,et al.  Insulin-like growth factors I and II: aging and bone density in women. , 1984, The Journal of clinical endocrinology and metabolism.

[33]  E. Froesch,et al.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. , 1981, The Journal of clinical investigation.

[34]  L C Murphy,et al.  Estrogen induces insulin-like growth factor-I expression in the rat uterus. , 1987, Molecular endocrinology.